omniture
logo
Search
江苏亚虹医药科技股份有限公司
Media Room

Latest News

rss

Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702

SHANGHAI, Nov. 11, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company with...

2020-11-11 17:08 1333

Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)

SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech com...

2020-11-05 13:59 1382

Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia

SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company spec...

2020-10-29 09:35 1962

Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech com...

2020-07-08 22:00 1358

Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019

SHANGHAI, Dec. 19, 2019 /PRNewswire/ -- Asieris, a China-based biotech company specializing in the ...

2019-12-19 13:51 2761
123